Oral daily PTH(1-34) tablets (EB613) in postmenopausal women with low BMD or osteoporosis: a randomized, placebo-controlled, 6-month, phase 2 study

Tripto-Shkolnik, L., Szalat, A., Tsvetov, G., Rouach, V., Sternberg, C., Hoppe, A., Burshtein, G., Galitzer, H., Toledano, M., Harari, G., Santora, A. C., & Cosman, F. (2024). Oral daily PTH(1-34) tablets (EB613) in postmenopausal women with low BMD or osteoporosis: a randomized, placebo-controlled, 6-month, phase 2 study. Journal of Bone and Mineral Research, 39(6), 672–682. https://doi.org/10.1093/jbmr/zjae057
Authors:
Liana Tripto-Shkolnik
Auryan Szalat
Gloria Tsvetov
Vanessa Rouach
Chana Sternberg
Anke Hoppe
Gregory Burshtein
Hillel Galitzer
Miranda Toledano
Gil Harari
Arthur C Santora
Felicia Cosman
Affiliated Authors:
Felicia Cosman
Columbia Affiliation:
Subjects:
Bone Density (MeSH)
Author Keywords:
osteoporosis treatment
oral teriparatide
oral pth
oral hpth(1-34)
osteoanabolics
ebp05/eb613
entera bio
elink
Publication Type:
Article
Unique ID:
10.1093/jbmr/zjae057
PMID:
38578978
DOI:
10.1093/jbmr/zjae057
Journal:
Journal of Bone and Mineral Research
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record
View Web of Science Record

Record Created: